Who makes cisplatin + docetaxel + enoxaparin?

cisplatin + docetaxel + enoxaparin is developed by University Hospital, Antwerp.

What development phase is cisplatin + docetaxel + enoxaparin in?

cisplatin + docetaxel + enoxaparin is in Phase 3.

Last reviewed 2026-04-19 · How we verify

cisplatin + docetaxel + enoxaparin

University Hospital, Antwerp · Phase 3 active Small molecule

At a glance

Generic name	cisplatin + docetaxel + enoxaparin
Also known as	Platinol, Taxotere, Clexane, LMWH
Sponsor	University Hospital, Antwerp
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

cisplatin + docetaxel + enoxaparin CI brief — competitive landscape report
cisplatin + docetaxel + enoxaparin updates RSS · CI watch RSS
University Hospital, Antwerp portfolio CI